Time to weight plateau with tirzepatide treatment in the SURMOUNT ‐1 and SURMOUNT ‐4 clinical trials

Jan 12, 2025Clinical obesity

Time to reach stable weight with tirzepatide treatment in SURMOUNT-1 and SURMOUNT-4 trials

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Median time to was 24.3 weeks for overweight participants in the SURMOUNT-1 trial.

Weight plateau was defined as a change of less than 5% over a 12-week period.
In SURMOUNT-1, 90.2% of participants reached a weight plateau by week 72.
Median time to weight plateau increased with higher BMI categories: 24.3 weeks for overweight, 26.0 weeks for class I, and 36.1 weeks for class II and III.
Factors associated with a longer time to weight plateau included higher doses of , younger age, and female sex.
Results from SURMOUNT-4 showed similar patterns regarding time to weight plateau.

AI simplified

The rate of weight reduction during obesity treatment declines over time and eventually reaches a . We investigated factors associated with time to weight plateau (TTWP) in -treated participants with obesity or overweight in a post-hoc analysis of SURMOUNT-1 and SURMOUNT-4 trials. Participants adherent to tirzepatide treatment and achieving ≥5% weight loss by primary endpoint (week 72 SURMOUNT-1; week 88 SURMOUNT-4) were included. Weight plateau was defined as a weight change <5% over a 12-week interval and all subsequent 12-week intervals. TTWP was time from randomization to the start of the first 12-week interval. Association between baseline characteristics and TTWP was assessed. Overall, 1438 participants in SURMOUNT-1 and 259 in SURMOUNT-4 were included. Across BMI categories (overweight, class I, II, and III), median TTWP in SURMOUNT-1 was 24.3, 26.0, 36.1, and 36.1 weeks, respectively (p <.05, class II and III vs. overweight). By week 72, 90.2%, 88.9%, 87.6%, and 87.8% of participants in SURMOUNT-1 had reached a weight plateau across respective BMI categories [Correction added on 22 January 2025, after first online publication: The "72%" has been changed to "72" in this version.]. Higher doses of tirzepatide (10/15 mg), younger age, and female sex were more likely to reach a weight plateau later. Results in SURMOUNT-4 were similar. In this post-hoc analysis, most participants reached a weight plateau by week 72. Higher doses of tirzepatide, younger age, and female sex were associated with a longer TTWP. Further research into modifiers of weight reduction phases with tirzepatide may inform treatment decisions for its use in chronic weight management. Clinical Trial Registration: ClinicalTrials.gov, identifiers NCT04184622 (SURMOUNT-1) and NCT04660643 (SURMOUNT-4), available at http://www.clinicaltrials.gov/.

Key numbers

24.3 weeks

Median

Median for overweight participants in SURMOUNT-1

90.2%

Achievement Rate

Proportion of participants in SURMOUNT-1 reaching

4.4 weeks

Longer with Higher Doses

Mean increase in with 10 mg vs. 5 mg

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Time to weight plateau with tirzepatide treatment in the SURMOUNT ‐1 and SURMOUNT ‐4 clinical trials

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief